ARLINGTON, Va., February 27, 2021 — HDA President and CEO
Chester “Chip” Davis, Jr., released a statement regarding the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization (EUA) for the Johnson & Johnson (Janssen Biotech) COVID-19 vaccine candidate:
“FDA’s authorization of a third COVID-19 vaccine candidate — a one-dose formulation — delivers additional hope that we will be able to provide more Americans greater access to vaccines while slowing the rate of infection. HDA appreciates the hard work of our manufacturer trading partners and the FDA in providing another option that strengthens the country’s fight against this virus.